ACADIA Pharmaceuticals Inc. (ACAD) Q4 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Thank you for standing by. My name is JL, and I will be your conference operator today. At this time, I would like to welcome everyone to the Acadia Pharmaceuticals Incorporated fourth quarter earnings call. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question and answer session. If you would like to ask a question during this time, simply press star, followed by the number one on your telephone keypad. If you would like to withdraw your question, simply press star one again. I would now like to turn the conference over to Alex. Kildani, Senior Vice President of Investor Relations and Corporate Communications. You may begin. Good afternoon, and thank you for joining us on today's call to discuss Acadia's fourth quarter and full year 2025 financial results. Joining me on the call today from Acadia are Catherine Owen Adams, our Chief Executive Officer, who will provide some opening remarks, followed by Tom Garner, our Chief Commercial Officer, who will discuss our commercial brands, Debut and New Placid. Also joining us today is Elizabeth Thompson, PhD, Executive Vice President, Head of Research and Development, who will provide an update on our pipeline programs, and Mark Schneier, our Chief Financial Officer, who will review the financial highlights. Katherine will then provide some closing thoughts before we open up the call to your questions. We are using supplemental slides, which are available on our website under the Events and Presentations section. On today's call, both GAAP and non-GAAP financial measures will be discussed, including non-GAAP New Plaza net sales and non-GAAP total revenues. The non-GAAP financial measures that are also referred to as adjusted financial measures are reconcile...